• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Strata Critical Medical Inc.

    11/19/25 5:07:28 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary
    Get the next $SRTA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001749370
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    STRATA CRITICAL MEDICAL, INC.
    SEC File Number
    001-39046
    Address of Issuer
    31 Hudson Yards, 14th Floor
    New York,
    NEW YORK
    10001
    Phone
    (585) 301-1762
    Name of Person for Whose Account the Securities are To Be Sold
    Reginald Lamonte Love
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    1100047433.108636652611/19/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/02/2024Restricted StockIssuerCheckbox not checked1100005/02/2024Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/19/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Reginald Lamonte Love

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SRTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Strata Critical Medical Hosts 2025 Investor Day; Provides 2026 and Medium-Term Financial Guidance

    Event highlights multiple ongoing industry growth catalysts and a range of factors that should enable Strata to grow faster than the overall marketTeam defines roll-up opportunity, acquisition philosophy and priority targets for $200 million of estimated cash available for deployment through 2029New 2026 financial guidance and medium-term financial framework targets a sustained high-teens target CAGR(1) for Adjusted EBITDA on an organic basisAdjusted EBITDA expected to double organically(1) by 2029, before capital deployment NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )) is hosting its 2025 Investor Day today at t

    11/17/25 2:00:00 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces Third Quarter 2025 Results

    Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1

    11/10/25 7:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces Date for Third Quarter Ending September 30, 2025 Earnings Release Conference Call

    NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b

    10/9/25 4:16:38 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Love Reginald sold $47,434 worth of shares (11,000 units at $4.31), decreasing direct ownership by 8% to 124,897 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    11/20/25 4:07:16 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Co-CEO and General Counsel Tomkiel Melissa M. exercised 27,778 shares at a strike of $0.18, increasing direct ownership by 2% to 1,400,420 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    11/12/25 4:20:11 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Chief Accounting Officer Cohen Amir was granted 41,786 shares and covered exercise/tax liability with 20,497 shares, increasing direct ownership by 21% to 121,342 units (SEC Form 4)

    4 - Strata Critical Medical, Inc. (0001779128) (Issuer)

    11/5/25 4:52:29 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    SEC Filings

    View All

    SEC Form S-8 filed by Strata Critical Medical Inc.

    S-8 - Strata Critical Medical, Inc. (0001779128) (Filer)

    11/21/25 4:51:04 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    SEC Form 144 filed by Strata Critical Medical Inc.

    144 - Strata Critical Medical, Inc. (0001779128) (Subject)

    11/20/25 4:05:58 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    SEC Form 144 filed by Strata Critical Medical Inc.

    144 - Strata Critical Medical, Inc. (0001779128) (Subject)

    11/19/25 5:07:28 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    $SRTA
    Financials

    Live finance-specific insights

    View All

    Strata Critical Medical Announces Third Quarter 2025 Results

    Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1

    11/10/25 7:00:00 AM ET
    $SRTA
    Transportation Services
    Consumer Discretionary

    Strata Critical Medical Announces Date for Third Quarter Ending September 30, 2025 Earnings Release Conference Call

    NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b

    10/9/25 4:16:38 PM ET
    $SRTA
    Transportation Services
    Consumer Discretionary